Self-Powered Microfluidic Device for Rapid Assay of Antiplatelet Drugs.

We report the development of a microfluidic device for the rapid assay in whole blood of interfacial platelet-protein interactions indicative of the efficacy of antiplatelet drugs, for example, aspirin and Plavix, two of the world's most widely used drugs, in patients with cardiovascular disease (CVD). Because platelet adhesion to surface-confined protein matrices is an interfacial phenomenon modulated by fluid shear rates at the blood/protein interface, and because such binding is a better indicator of platelet function than platelet self-aggregation, we designed, fabricated, and characterized the performance of a family of disposable, self-powered microfluidic chips with well-defined flow and interfacial shear rates suitable for small blood volumes (≤200 µL). This work demonstrates that accurate quantification of cell adhesion to protein matrices, an important interfacial biological phenomenon, can be used as a powerful diagnostic tool in those with CVD, the world's leading cause of death. To enable such measurements, we developed a simple technique to fabricate single-use self-powered chips incorporating shear control (SpearChips). These parallel-plate flow devices integrate on-chip vacuum-driven blood flow, using a predegassed elastomer component to obviate active pumping, with microcontact-printed arrays of 6-µm-diameter fluorescently labeled fibrinogen dots on a cyclic olefin polymer base plate as a means to quantitatively count platelet-protein binding events. The use of SpearChips to assess in whole blood samples the effects of GPIIb/IIIa and P2Y12 inhibitors, two important classes of "antiplatelet" drugs, is reported.

Pulsed-Plasma Physical Vapor Deposition Approach Toward the Facile Synthesis of Multilayer and Monolayer Graphene for Anticoagulation Applications.

We demonstrate the growth of multilayer and single-layer graphene on copper foil using bipolar pulsed direct current (DC) magnetron sputtering of a graphite target in pure argon atmosphere. Single-layer graphene (SG) and few-layer graphene (FLG) films are deposited at temperatures ranging from 700 °C to 920 °C within <30 min. We find that the deposition and post-deposition annealing temperatures influence the layer thickness and quality of the graphene films formed. The films were characterized using atomic force microscopy (AFM), scanning electron microscopy (SEM), high-resolution transmission electron microscopy (HRTEM), Raman spectroscopy, X-ray photoelectron spectroscopy (XPS), and optical transmission spectroscopy techniques. Based on the above studies, a diffusion-controlled mechanism was proposed for the graphene growth. A single-step whole blood assay was used to investigate the anticoagulant activity of graphene surfaces. Platelet adhesion, activation, and morphological changes on the graphene/glass surfaces, compared to bare glass, were analyzed using fluorescence microscopy and SEM techniques. We have found significant suppression of the platelet adhesion, activation, and aggregation on the graphene-covered surfaces, compared to the bare glass, indicating the anticoagulant activity of the deposited graphene films. Our production technique represents an industrially relevant method for the growth of SG and FLG for various applications including the biomedical field.

Individual platelet adhesion assay: measuring platelet function and antiplatelet therapies in whole blood via digital quantification of cell adhesion.

Widespread monitoring of platelet function and the effect of antiplatelet drugs will improve outcomes in cardiovascular patients, but platelet function testing is not routine in clinical practice. We report a rapid, accurate methodology to quantify platelet-protein interactions: a microarray of contact-printed 6-µm fibrinogen dots on a transparent substrate binds platelets from whole blood, one platelet per dot. The fractional occupancy of an array of fibrinogen dots after a predefined incubation time quantitatively assays platelet adhesion to the protein matrix. We demonstrate this technique by measurement of platelet adhesion to fibrinogen as a means to quantify the effect of the P2Y12 and αIIbß3 receptor inhibitors cangrelor and abciximab, respectively, both in vitro--by incubating the drug with a freshly drawn blood sample--and in blood from patients treated with antiplatelet agents. The effects of single- and dual-antiplatelet therapy are also assessed. Results from this platelet-binding assay are well correlated with standard techniques including flow cytometry and light transmission aggregometry. This assay technology, readily integrated with microfluidic platforms, is generally applicable to the assay of cell-protein interactions and promises more effective, rapid assay of drug effects in cardiovascular disease patients.

Lipid bilayer assembly at a gold nanocavity array.

The assembly of lipid bilayer membranes, using ultrasonic disruption of liposomes of L-α-Dimyristoyl phosphatidylcholine, across 820 nm diameter spherical cap gold cavity arrays is demonstrated.

Regio-selective decoration of nanocavity metal arrays: contributions from localized and delocalized plasmons to surface enhanced Raman spectroscopy.

Spherical cap gold nanocavity arrays with internal diameters of 240, 430, 600 and 820 nm were fabricated on smooth gold films using nanosphere lithography with electrochemical metal deposition. Each array was prepared to the same normalized film thickness to diameter ratios, t(N), of 0.8 ± 0.04. Selective modification of the top surface and interior walls of the gold nanocavity arrays with [Ru(bpy)(2)(Qbpy)](2+), where bpy is 2,2'-bipyridyl and Qbpy is 2,2':4,4'':4,4''-quarterpyridyl, was accomplished using a two step adsorption process exploiting the assembled polystyrene spheres as masks. This selective modification approach permitted direct quantitative comparison, for the first time, of plasmonic enhancement of Raman signal and luminescence signal from a monolayer adsorbed at the top surface versus interior walls of all-gold nanocavity arrays. For all cavity sizes, significantly greater Raman and luminescence signal enhancement was observed from [Ru(bpy)(2)(Qbpy)](2+) monolayer adsorbed at the top surface of the array compared with the cavity walls. This disparity in Raman intensity from top versus cavity interior increased as the cavity dimensions decreased. For example, the Raman signal intensity from [Ru(bpy)(2)(Qbpy)](2+) adsorbed at the top surface of 240 nm gold arrays was 170 times greater than SERS signal for this material adsorbed at the interior walls of this array, whereas the relative Raman signal enhancement was 6 from top versus interior for the 820 nm internal radius arrays under 785 nm excitation. The origin of the relatively greater signal at the top surface is discussed in the context of plasmonic distribution at each surface.

Protein nanopatterning and release from gold nano-cavity arrays.

Selective chemical modification of a gold nano-cavity array is achieved via nanoscale templating to create fibrinogen patterned cavities with a polyethylene glycol modified top surface. Application of a reducing potential to the array readily releases the protein from the cavities.

Emission enhancement within gold spherical nanocavity arrays.

Gold nanocavity arrays were prepared on fluorine-doped tin oxide on glass by electrochemical deposition of gold through monolayers of polystyrene spheres. The impact of the resulting spherical cap architecture on the photophysics of solutions and self-assembled monolayers of luminophore encapsulated within the nanocavities is reported for the first time. From conventional confocal fluorescence microscopy, the emission intensity of solutions of [Ru(bpy)(2)(Qbpy)](2+) (where bpy is 2,2'-bipyridyl and Qbpy is 2,2':4,4'':4,4''-quarterpyridyl) and fullerene (C(60)) encapsulated within the 820 nm diameter nanocavities was demonstrated to increase by approximately an order of magnitude compared with that of the associated bulk solution. Comparison was also made with the emission observed for luminophore solution encapsulated in cobalt nanocavities of comparable dimensions, where plasmonic interactions are not anticipated. Again, approximately an order of magnitude enhancement was observed for the gold arrays. Luminescence lifetime imaging revealed that the enhancement of the emission intensity of this solution within the nanocavity was accompanied by a small but significant decrease in the luminescent lifetime for [Ru(bpy)(2)(Qbpy)](2+). Enhancement was, in addition, strongly influenced by the wavelength of excitation, suggesting that plasmonics may play a role in the enhancement of the excitation process. An important observation from confocal imaging studies was that the dimensions of the luminophore emission field from solution within the cavities were significantly smaller than the dimensions of the cavity aperture and corresponded to a little more than that of the point spread function of the microscope. This indicates that its origin is significantly smaller than the wavelength of the emitted light and suggests that luminescence enhancement is highly localised. When the array was filled with a solution of [Ru(bpy)(2)(Qbpy)](2+) the emission spectrum of this complex was red shifted and broadened compared with that of the bulk solution, typical of the formation of a luminescent surface film. In addition, significant enhancement was only observed when the solution was sonicated into the array. Both these observations suggest that the emission enhancement is localised near the bottom of the cavity. Self-assembled monolayers of [Ru(bpy)(2)(Qbpy)](2+) were formed on the array and approximately 7 orders of magnitude enhancement of the Raman signal was achieved. Significantly, the emission intensity was approximately 4-fold higher for the monolayer than for a solid film under the same conditions, but surface quenching is thought to play a significant role in the observed decrease in lifetime for the monolayer of this complex on the array.